Which advantages over its rivals hold up, and why are they hard to copy?
XNApharma's durable advantage is selective activation: its peptide-inhibited siRNA prodrug becomes active only in target cancer cells where a specific protease cleaves the peptide, while non-target cells degrade the prodrug with nucleases instead of activating it, which prevents side effects in those cells.
Because activation cleaves the delivery structures from the siRNA, XNApharma faces fewer size, charge, and hydrophobicity limitations than standard design strategies.
2Growth Drivers
What could change its growth trajectory, and what would confirm it?
Growth turns on XNApharma advancing from a final round of preclinical testing into clinical trials that analyze the efficacy and tolerability of its potential drug, its next stated goal, pursued as a partner of a German therapeutic-nucleic-acid network whose cooperation began in 2025.
The network partners held their first joint kick-off meeting on 24.04.2025 at partner GWT-TUD in Dresden. A third party learned about the Network for Therapeutic Nucleic Acids through four named companies including XNApharma and plans to reach out to explore cooperation opportunities.
3Product Overview
What does the product do for its buyer, and how is it delivered?
XNApharma operates as a single point of contact for oligonucleotide development, spanning ASO, siRNA, aptamer and CpG oligonucleotides plus gRNA, mRNA and delivery approaches.
Delivery runs through laboratory services, consulting, and process-wide network support. XNApharma partners with university hospitals, clinical research teams and patient initiatives on individualized clinical trials.
XNApharma
BianoScience is a privately owned biotechnology company focused on oligonucleotides, offering oligonucleotide development as a service.